Further characterization of Shigella-specific (memory) B cells induced in healthy volunteer recipients of SF2a-TT15, a Shigella flexneri 2a synthetic glycan-based vaccine candidate
Shigellosis is common worldwide, and it causes significant morbidity and mortality mainly in young children in low- and middle- income countries. To date, there are not broadly available licensed Shigella vaccines. A novel type of conjugate vaccine candidate, SF2a-TT15, was developed against S. flexneri serotype 2a (SF2a). SF2a-TT15 is composed of a synthetic 15mer oligosaccharide, designed to act as a functional mimic of the SF2a O-antigen and covalently linked to tetanus toxoid (TT). SF2a-TT15 was recently shown to be safe and immunogenic in a Phase 1 clinical trial, inducing specific memory B cells and sustained antibod...
Source: Frontiers in Immunology - October 31, 2023 Category: Allergy & Immunology Source Type: research
Vaccination compliance of selected childhood immunization programs and the socio-determinant factors in Nigeria
Conclusions: The socio-cultural factors associated with achieving full vaccination coverage in Nigeria in this study should drive the implementation of policies that will be best suited to each geopolitical zone of Nigeria. (Source: The Journal of Infection in Developing Countries)
Source: The Journal of Infection in Developing Countries - October 31, 2023 Category: Infectious Diseases Authors: Oluyemi A Okunlola, Olawunmi R Oyerinde, Imisioluwa D Fashina, Oyetunde T Oyeyemi Source Type: research
The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023
This study can inform future demands for increased inclusion, especially in industry-sponsored trials, as it provides an overview of the current vaccine trials scene.PMID:37903681 | DOI:10.1016/j.vaccine.2023.10.057 (Source: Vaccine)
Source: Vaccine - October 30, 2023 Category: Allergy & Immunology Authors: Maha Salloum Antea Paviotti Hilde Bastiaens Jean-Pierre Van Geertruyden Source Type: research
The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023
This study can inform future demands for increased inclusion, especially in industry-sponsored trials, as it provides an overview of the current vaccine trials scene.PMID:37903681 | DOI:10.1016/j.vaccine.2023.10.057 (Source: Vaccine)
Source: Vaccine - October 30, 2023 Category: Allergy & Immunology Authors: Maha Salloum Antea Paviotti Hilde Bastiaens Jean-Pierre Van Geertruyden Source Type: research
The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023
This study can inform future demands for increased inclusion, especially in industry-sponsored trials, as it provides an overview of the current vaccine trials scene.PMID:37903681 | DOI:10.1016/j.vaccine.2023.10.057 (Source: Vaccine)
Source: Vaccine - October 30, 2023 Category: Allergy & Immunology Authors: Maha Salloum Antea Paviotti Hilde Bastiaens Jean-Pierre Van Geertruyden Source Type: research
Background rates for severe cutaneous reactions in the US: Contextual support for safety assessment of COVID-19 vaccines and novel biologics
Vaccine. 2023 Oct 25:S0264-410X(23)01208-2. doi: 10.1016/j.vaccine.2023.10.025. Online ahead of print.ABSTRACTThe global COVID-19 public health crisis has resulted in extraordinary collaboration to expeditiously develop vaccines and therapeutics. The safety of these biologics is closely monitored by the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Novel products may have limited safety data, and although serious medical outcomes associated with vaccination are rare, knowledge of background incidence rates of medical conditions in the US population puts reported adverse eve...
Source: Vaccine - October 27, 2023 Category: Allergy & Immunology Authors: Diane Gubernot Mikhail Menis Barbee Whitaker Source Type: research
Background rates for severe cutaneous reactions in the US: Contextual support for safety assessment of COVID-19 vaccines and novel biologics
Vaccine. 2023 Oct 25:S0264-410X(23)01208-2. doi: 10.1016/j.vaccine.2023.10.025. Online ahead of print.ABSTRACTThe global COVID-19 public health crisis has resulted in extraordinary collaboration to expeditiously develop vaccines and therapeutics. The safety of these biologics is closely monitored by the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Novel products may have limited safety data, and although serious medical outcomes associated with vaccination are rare, knowledge of background incidence rates of medical conditions in the US population puts reported adverse eve...
Source: Vaccine - October 27, 2023 Category: Allergy & Immunology Authors: Diane Gubernot Mikhail Menis Barbee Whitaker Source Type: research
Background rates for severe cutaneous reactions in the US: Contextual support for safety assessment of COVID-19 vaccines and novel biologics
Vaccine. 2023 Oct 25:S0264-410X(23)01208-2. doi: 10.1016/j.vaccine.2023.10.025. Online ahead of print.ABSTRACTThe global COVID-19 public health crisis has resulted in extraordinary collaboration to expeditiously develop vaccines and therapeutics. The safety of these biologics is closely monitored by the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Novel products may have limited safety data, and although serious medical outcomes associated with vaccination are rare, knowledge of background incidence rates of medical conditions in the US population puts reported adverse eve...
Source: Vaccine - October 27, 2023 Category: Allergy & Immunology Authors: Diane Gubernot Mikhail Menis Barbee Whitaker Source Type: research
Routine Vaccination Coverage - Worldwide, 2022
This report reviews trends in World Health Organization and UNICEF immunization coverage estimates at global, regional, and national levels through 2022 and documents progress toward improving coverage with respect to the IA2030 strategy, which aims to reduce the number of children who have not received the first dose of a diphtheria-tetanus-pertussis-containing vaccine (DTPcv1) worldwide by 50% and to increase coverage with 3 diphtheria-tetanus-pertussis-containing vaccine doses (DTPcv3) to 90%. Worldwide, coverage ≥1 dose of DTPcv1 increased from 86% in 2021 to 89% in 2022 but remained below the 90% coverage achieved i...
Source: MMWR Morb Mortal Wkl... - October 26, 2023 Category: Epidemiology Authors: Gurpreet Kaur M Carolina Danovaro-Holliday George Mwinnyaa Marta Gacic-Dobo Lauren Francis Jan Grevendonk Samir V Sodha Ciara Sugerman Aaron Wallace Source Type: research
Routine Vaccination Coverage - Worldwide, 2022
This report reviews trends in World Health Organization and UNICEF immunization coverage estimates at global, regional, and national levels through 2022 and documents progress toward improving coverage with respect to the IA2030 strategy, which aims to reduce the number of children who have not received the first dose of a diphtheria-tetanus-pertussis-containing vaccine (DTPcv1) worldwide by 50% and to increase coverage with 3 diphtheria-tetanus-pertussis-containing vaccine doses (DTPcv3) to 90%. Worldwide, coverage ≥1 dose of DTPcv1 increased from 86% in 2021 to 89% in 2022 but remained below the 90% coverage achieved i...
Source: MMWR Morb Mortal Wkl... - October 26, 2023 Category: Epidemiology Authors: Gurpreet Kaur M Carolina Danovaro-Holliday George Mwinnyaa Marta Gacic-Dobo Lauren Francis Jan Grevendonk Samir V Sodha Ciara Sugerman Aaron Wallace Source Type: research
Routine Vaccination Coverage - Worldwide, 2022
This report reviews trends in World Health Organization and UNICEF immunization coverage estimates at global, regional, and national levels through 2022 and documents progress toward improving coverage with respect to the IA2030 strategy, which aims to reduce the number of children who have not received the first dose of a diphtheria-tetanus-pertussis-containing vaccine (DTPcv1) worldwide by 50% and to increase coverage with 3 diphtheria-tetanus-pertussis-containing vaccine doses (DTPcv3) to 90%. Worldwide, coverage ≥1 dose of DTPcv1 increased from 86% in 2021 to 89% in 2022 but remained below the 90% coverage achieved i...
Source: MMWR Morb Mortal Wkl... - October 26, 2023 Category: Epidemiology Authors: Gurpreet Kaur M Carolina Danovaro-Holliday George Mwinnyaa Marta Gacic-Dobo Lauren Francis Jan Grevendonk Samir V Sodha Ciara Sugerman Aaron Wallace Source Type: research
Routine Vaccination Coverage - Worldwide, 2022
This report reviews trends in World Health Organization and UNICEF immunization coverage estimates at global, regional, and national levels through 2022 and documents progress toward improving coverage with respect to the IA2030 strategy, which aims to reduce the number of children who have not received the first dose of a diphtheria-tetanus-pertussis-containing vaccine (DTPcv1) worldwide by 50% and to increase coverage with 3 diphtheria-tetanus-pertussis-containing vaccine doses (DTPcv3) to 90%. Worldwide, coverage ≥1 dose of DTPcv1 increased from 86% in 2021 to 89% in 2022 but remained below the 90% coverage achieved i...
Source: MMWR Morb Mortal Wkl... - October 26, 2023 Category: Epidemiology Authors: Gurpreet Kaur M Carolina Danovaro-Holliday George Mwinnyaa Marta Gacic-Dobo Lauren Francis Jan Grevendonk Samir V Sodha Ciara Sugerman Aaron Wallace Source Type: research
Routine Vaccination Coverage - Worldwide, 2022
This report reviews trends in World Health Organization and UNICEF immunization coverage estimates at global, regional, and national levels through 2022 and documents progress toward improving coverage with respect to the IA2030 strategy, which aims to reduce the number of children who have not received the first dose of a diphtheria-tetanus-pertussis-containing vaccine (DTPcv1) worldwide by 50% and to increase coverage with 3 diphtheria-tetanus-pertussis-containing vaccine doses (DTPcv3) to 90%. Worldwide, coverage ≥1 dose of DTPcv1 increased from 86% in 2021 to 89% in 2022 but remained below the 90% coverage achieved i...
Source: MMWR Morb Mortal Wkl... - October 26, 2023 Category: Epidemiology Authors: Gurpreet Kaur M Carolina Danovaro-Holliday George Mwinnyaa Marta Gacic-Dobo Lauren Francis Jan Grevendonk Samir V Sodha Ciara Sugerman Aaron Wallace Source Type: research
Routine Vaccination Coverage - Worldwide, 2022
This report reviews trends in World Health Organization and UNICEF immunization coverage estimates at global, regional, and national levels through 2022 and documents progress toward improving coverage with respect to the IA2030 strategy, which aims to reduce the number of children who have not received the first dose of a diphtheria-tetanus-pertussis-containing vaccine (DTPcv1) worldwide by 50% and to increase coverage with 3 diphtheria-tetanus-pertussis-containing vaccine doses (DTPcv3) to 90%. Worldwide, coverage ≥1 dose of DTPcv1 increased from 86% in 2021 to 89% in 2022 but remained below the 90% coverage achieved i...
Source: MMWR Morb Mortal Wkl... - October 26, 2023 Category: Epidemiology Authors: Gurpreet Kaur M Carolina Danovaro-Holliday George Mwinnyaa Marta Gacic-Dobo Lauren Francis Jan Grevendonk Samir V Sodha Ciara Sugerman Aaron Wallace Source Type: research
